A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells 2021 Aug 02;10(8)
Date
08/28/2021Pubmed ID
34440730Pubmed Central ID
PMC8391934DOI
10.3390/cells10081961Scopus ID
2-s2.0-85115041797 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Multiple myeloma (MM) is a blood cancer characterized by the accumulation of malignant monoclonal plasma cells in the bone marrow. It develops through a series of premalignant plasma cell dyscrasia stages, most notable of which is the Monoclonal Gammopathy of Undetermined Significance (MGUS). Significant advances have been achieved in uncovering the genomic aberrancies underlying the pathogenesis of MGUS-MM. In this review, we discuss in-depth the genomic evolution of MM and focus on the prognostic implications of the accompanied molecular and cytogenetic aberrations. We also dive into the latest investigatory techniques used for the diagnoses and risk stratification of MM patients.
Author List
Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal BAuthors
Binod Dhakal MD Associate Professor in the Medicine department at Medical College of WisconsinJing Dong PhD Assistant Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Ataxia Telangiectasia Mutated ProteinsGene Expression
Humans
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Poly(ADP-ribose) Polymerase Inhibitors
Polymorphism, Single Nucleotide
Prognosis
Tumor Suppressor Protein p53
ras Proteins
